Clinical Trials Logo

Filter by:
NCT ID: NCT04739384 Completed - Clinical trials for Coronary Artery Disease

Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS

PlinytheElder
Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

Elderly individuals are increasingly represented among patients with acute coronary syndrome (ACS). Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 receptor inhibitor has an established role in the prevention of atherothrombotic events in ACS setting. However, DAPT in older patients is challenged by a concurrent heightened risk of ischemia and bleeding. Although guidelines recommend DAPT with aspirin and ticagrelor for elderly patients with ACS, clopidogrel, a less potent antiplatelet agent, continues to be used in more than one third of ACS patients with elderly status being the strongest predictor of undertreatment. A lower dose of ticagrelor may represent an alternative to the standard dose by conferring a similar efficacy and, potentially, a better safety profile. Our prospective, randomized, double-blind, crossover trial will test the hypothesis that a lower dose of ticagrelor provides similar antiplatelet effects compared with a standard dose among elderly patients with ACS. The main aim of the trial is to determine the pharmacodynamic and pharmacokinetic profile of ticagrelor 60 mg twice daily versus ticagrelor 90 mg twice daily among elderly patients with ACS undergoing PCI. This will be a prospective, randomized (1:1 ratio), non-inferiority, open-label, crossover trial to evaluate the level of platelet inhibition achieved with a low-dose of ticagrelor (60 mg twice daily) versus a standard dose of ticagrelor (90 mg twice daily) among elderly patients with ACS undergoing PCI.

NCT ID: NCT04740281 Completed - Shoes Clinical Trials

Footwear Among Medical Doctors

TÅFIS
Start date: April 1, 2021
Phase:
Study type: Observational

The footwear fashion among medical doctors has been static for decades with a high preference for clogs. However, other types of shoes have been introduced, including sneakers, sandals etc. In some subspecialties with a "need-for-speed", high-agility footwear may be prioritized, while other subspecialist may benefit from "easy-to-clean" shoes. Even comfortability may influence the choice of footwear. We intend to investigate measures of footwear fashion among medical doctors working at Aarhus University Hospital, Denmark. Participants will be blinded.

NCT ID: NCT04748315 Completed - Muscle Damage Clinical Trials

Recovery Kinetics After Speed-Εndurance Maintenance Training

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study will be to inestigate the recovery kinetics on performance, neuromuscular fatigue and muscle microtaruma that will occur after two speed-endurance maintenance training protocols in elite male soccer players. Also, this study will determine the comparison between two different speed endurance maintenance protocols in neuromuscular fatigue, muscle microtrauma indicators and performance factors. The training protocols will be differentiated in training work to rest ratio. The firts training protocol trial will comprise the work to rest ratio (1:1) and the other trial will comprise the work to rest ratio 1:3.

NCT ID: NCT04749251 Completed - Clinical trials for Acute Ischemic Stroke

IDEAL Blood Pressure Management During Endovascular Therapy for Acute Ischemic Stroke

IDEAL
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The ideal blood pressure management strategy during endovascular therapy (EVT) for acute ischemic stroke has not been defined. The aim of this pilot randomized clinical trial is to determine whether randomization to a standard versus individual blood pressure management strategy during the EVT procedure is feasible.

NCT ID: NCT04750330 Completed - Covid19 Clinical Trials

Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection

mtDNA-COVID
Start date: April 1, 2021
Phase:
Study type: Observational

In December 2019, the first people got infected with COVID-19 in Wuhan, China. Within weeks, this highly infectious disease spread all over the world. Nearly one year later everyone is still trying to battle this disease and facing the consequences it causes. What became clear is that the disease and its severity differs largely between infected people. However, knowledge about who will experience severe COVID-19 and who does not is still unclear. Therefore, the aim of this study is to investigate the prognostic value of certain parameters (mtDNA and CT radiomics signature) for the severity of COVID-19.

NCT ID: NCT04754724 Completed - Lactose Intolerance Clinical Trials

Evaluation of GIMate Handheld Hydrogen Breath Monitor for Diagnosis of Lactose Malabsorption

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The goal of this study is to assess the performance of the Vivante Health GIMate Breathalyzer device in diagnosing lactose malabsorption.

NCT ID: NCT04757402 Completed - Clinical trials for Satisfaction, Patient

Role of Preoperative Counselling With NSQIP Surgical Risk Calculator

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Surgical patients undergo preoperative counseling which varies in quality and duration. Proper communication during the preoperative consultation can deliver relevant health information and guide improvement of perioperative health status. The methods, however, are non-standardized and the explanation of the postoperative course is generally vague or varies from person to person. We hypothesize that high-risk patients who receive pre-operative counseling with the help of the NSQIP surgical risk calculator compared to the current standard of care will have higher satisfaction concerning information on the perioperative journey.

NCT ID: NCT04757584 Completed - Heart Failure Clinical Trials

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

Start date: April 1, 2021
Phase: Phase 4
Study type: Interventional

In this study, we will test the feasibility of N-of-1 trials for deprescribing beta-blockers in patients with Heart Failure with Preserved Ejection Fraction. To achieve this objective we will conduct 16 4-period N-of-1 trials (on vs. off) and subsequently interview participants to better understand feasibility and pragmatism. The N-of-1 trials will be iteratively refined in real-time based on this feedback.

NCT ID: NCT04760184 Completed - Covid19 Clinical Trials

Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden

AutoCOVID-19
Start date: April 1, 2021
Phase:
Study type: Observational

This retrospective observational cohort study aims to describe the impact of COVID-19 in patients treated with autologous stem cell transplantation (ASCT) for malignant disease in terms of risk factors, morbidity, need for supportive care and mortality. All patients treated with ASCT in Sweden from 1st January 2020 until 31st December 2020 are eligible for this study. Patients who also has tested positive for SARS-CoV-2 from start of conditioning or later will be identified through the national registry of the Public Health Agency of Sweden and a systematic analysis of their medical records will be performed.

NCT ID: NCT04763707 Completed - Clinical trials for Hepatocellular Carcinoma

Serum Visfatin and Serum Vaspin in Patients With Hepatocellular Carcinoma on Top of Liver Cirrhosis

Start date: April 1, 2021
Phase:
Study type: Observational [Patient Registry]

Hepatocellular carcinoma (HCC) has a global importance due to its high rate of progression and high mortality rates. Significant risk factors for the development of HCC are metabolic syndrome, obesity and type 2 diabetes mellitus(T2DM). Dysregulation of adipose tissue derived hormones(adipocytokines/adipokines) might also be involved in obesity-related liver carcinogenesis & due to the wide spectrum of visfatin and vaspin activities ,we focus in this study on their potential role in patients with HCV-related liver cirrhosis with and without HCC on top.